Clinical Trials Browser

Phase 2 × HER2/Neu Negative × 90 days × Clear all

NCT02398773 2026-04-21

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Phase 2 Active not recruiting

HER2/Neu Negative